© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Kairos Pharma, Ltd. (KAPA) shows an Average True Range (ATR) of 0.07 and an Enterprise Value of N/A. Its average trading volume over the past 3 months is 310.9K, indicating liquidity. These fundamental metrics provide insight into KAPA's underlying financial health and market activity.
Kairos Pharma, Ltd. (KAPA) technical indicators as of December 22, 2025: the SMA 20 is 7.55%, SMA 50 at -7.01%, and SMA 200 at -9.38%. The RSI 14 value is 52.69, suggesting its current momentum. These technical analysis signals help assess KAPA's price trends and potential future movements.
Kairos Pharma, Ltd. (KAPA) stock performance overview as of December 22, 2025: The 52-week high is $3.25 (currently -73.59% below), and the 52-week low is $0.4 (currently 114.6% above). Over the past year, KAPA's performance is -49.51%, compared to the S&P 500's 12.87% change.
According to market data, Kairos Pharma, Ltd. (KAPA) stock's recent performance metrics show that over the last month, KAPA is 14.42%, with a Year-to-Date (YTD) performance of -43.53%. Over the past year, the stock has seen a -49.51% change. These figures summarize KAPA's price movements across various periods, reflecting its historical returns.
According to current financial data, KAPA stock's P/E (TTM) ratio is -3.43, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for KAPA, including P/S (N/A), P/B (2.26), and P/FCF (-4.28), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.